- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
51 result(s) found for: Gender related factors.
Displaying page 1 of 3.
| EudraCT Number: 2020-001501-24 | Sponsor Protocol Number: IRST100.47 | Start Date*: 2020-04-28 | |||||||||||
| Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
| Full Title: PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). | |||||||||||||
| Medical condition: Group 1: SARS-CoV-2-exposed subjects, as household members/contacts of COVID-19 patients Group 2: Patients with COVID-19 asymptomatic or paucisymptomatic in home situation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-000461-28 | Sponsor Protocol Number: Resubmission A | Start Date*: 2008-06-10 | ||||||||||||||||
| Sponsor Name:Karolinska institutet | ||||||||||||||||||
| Full Title: Effect of exercise or metformin on nocturnal blood pressure and other risk factors for cardiovascular heart disease among obese adolescents | ||||||||||||||||||
| Medical condition: The aim is to, among obese adolescents study impact of exercise or metformin therapy on nocturnal blood pressure and related cardiovascular disease risk factors (e.g. insulin sensitivity, IMT, LVM,... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SE (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2015-000233-73 | Sponsor Protocol Number: HCQvJan11 | Start Date*: 2016-01-05 |
| Sponsor Name:Helsinki University Central Hospital | ||
| Full Title: HYDROXYCHLOROQUINE IN ACUTE CORONARY SYNDROME: PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS | ||
| Medical condition: Cardiovascular disease | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-002431-18 | Sponsor Protocol Number: NN9536-4451 | Start Date*: 2019-09-25 | ||||||||||||||||
| Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
| Full Title: Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity | ||||||||||||||||||
| Medical condition: Overweight Obesity | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) IE (Completed) HR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2014-003641-95 | Sponsor Protocol Number: SELECTI-CARFAP | Start Date*: 2015-02-13 | |||||||||||
| Sponsor Name:Nicasio Pérez Castellano | |||||||||||||
| Full Title: Randomized clinical trial to study effective pharmacological cardioversion of paroxysmal atrial fibrillation by blocking ionic currents atrioselectivas by treatment with vernakalant vs Flecainide | |||||||||||||
| Medical condition: Atrial fibrillation paroxysmal | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000546-34 | Sponsor Protocol Number: NN8022-4392 | Start Date*: 2021-02-10 | |||||||||||
| Sponsor Name:Novo Nordisk A/S | |||||||||||||
| Full Title: Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial | |||||||||||||
| Medical condition: Obesity | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) PT (Trial now transitioned) NO (Not Authorised) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-003970-89 | Sponsor Protocol Number: CICL670ADE02 | Start Date*: 2007-12-21 | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplan... | |||||||||||||
| Medical condition: allogeneic hematopoietic cell transplantation with iron overload | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-000259-35 | Sponsor Protocol Number: 2020_03 | Start Date*: 2022-04-29 | |||||||||||
| Sponsor Name:Centre Hospitalier Universitaire de Lille | |||||||||||||
| Full Title: Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections | |||||||||||||
| Medical condition: Overactive bladder (OAB) and/or detrusor overactivity (DO) in multiple sclerosis (MS) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004106-34 | Sponsor Protocol Number: Dastop2October17th2016 | Start Date*: 2017-03-06 |
| Sponsor Name:Uppsala University Hospital | ||
| Full Title: PERSISTENCE OF MAJOR MOLECULAR REMISSION IN CHRONIC MYELOID LEUKEMIA AFTER a second stop of TKI TREATMENT in patients who failed an initial stop attempt: A prospective multicenter study . | ||
| Medical condition: Chronic Myeloid Leukemia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-001282-17 | Sponsor Protocol Number: E7389-G000-223 | Start Date*: 2018-03-23 |
| Sponsor Name:Eisai Inc. | ||
| Full Title: A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma S... | ||
| Medical condition: Relapsed/Refractory Rhabdomyosarcoma Non-rhabdomyosarcoma Soft Tissue Sarcoma Ewing Sarcoma | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2008-003774-17 | Sponsor Protocol Number: 483-001 | Start Date*: 2008-08-01 | |||||||||||
| Sponsor Name:Vantia Ltd | |||||||||||||
| Full Title: A double-blind, placebo-controlled dose response study to investigate pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483 in elderly male subjects | |||||||||||||
| Medical condition: Nocturia. | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-003416-31 | Sponsor Protocol Number: FAEDV-2012-01 | Start Date*: 2013-02-22 |
| Sponsor Name:Fundación Academia Española de Dermatología y Venereología | ||
| Full Title: Multicenter, randomized, open clinical trial comparing three sessions of methyl-aminolevulinate 16% (Metvix®) photodynamic therapy versus a group without photodynamic therapy to treat onychomycosis. | ||
| Medical condition: onychomycosis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-002748-10 | Sponsor Protocol Number: AD-02-013 | Start Date*: 2013-12-12 |
| Sponsor Name:Fundación para la Investigación en Enfermedades del Aparato Digestivo | ||
| Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreati... | ||
| Medical condition: Patients with pancreatic exocrine insufficiency (PEI) secondary to type 1 diabetes mellitus (DM) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-001518-13 | Sponsor Protocol Number: 10407 | Start Date*: 2018-11-12 |
| Sponsor Name:Maatschap Cardiologie Zwolle | ||
| Full Title: Comparison between treatment with catheter ablation or anti-arrhythmic drugs (sotalol or combination of verapamil and flecainide) of patients with benign ventricular premature beats and ventricular... | ||
| Medical condition: Premature ventricular beats, ventricular ectopy, ventricle tachycardia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004564-59 | Sponsor Protocol Number: Pontrack01 | Start Date*: 2019-08-29 |
| Sponsor Name:Heidelberg University | ||
| Full Title: WITH PONATINIB ON THE TRACK FOR TREATMENT-FREE-REMISSION IN CHRONIC MYELOID LEUKEMIA | ||
| Medical condition: chronic myeloid leukemia in chronic phase | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-003778-29 | Sponsor Protocol Number: CTU/2013/064 | Start Date*: 2014-01-30 | |||||||||||
| Sponsor Name:University College London | |||||||||||||
| Full Title: Combined Multi-Marker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Pre-eclampsia Prevention | |||||||||||||
| Medical condition: Pre-eclampsia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) IT (Completed) BE (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-002311-64 | Sponsor Protocol Number: SuloPrima | Start Date*: 2021-10-01 | |||||||||||
| Sponsor Name:ALFASIGMA CZECH s.r.o. | |||||||||||||
| Full Title: Efficacy and safety of sulodexide in the treatment of chronic primary venous disease of the lower extremities: randomized double-blind placebo-controlled clinical trial | |||||||||||||
| Medical condition: Chronic primary venous disease of the lower limbs | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-006134-17 | Sponsor Protocol Number: IPM3002 | Start Date*: 2012-07-30 | |||||||||||
| Sponsor Name:ZIOPHARM Oncology, Inc. | |||||||||||||
| Full Title: A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etopo... | |||||||||||||
| Medical condition: Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) HU (Completed) PL (Completed) IT (Completed) DE (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002554-23 | Sponsor Protocol Number: GENA-05 | Start Date*: 2013-02-19 | |||||||||||
| Sponsor Name:OCTAPHARMA AG | |||||||||||||
| Full Title: Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A | |||||||||||||
| Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: GB (Completed) PL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SI (Completed) HR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001033-40 | Sponsor Protocol Number: VS-6063-202 | Start Date*: 2013-07-26 | |||||||||||
| Sponsor Name:Verastem Inc | |||||||||||||
| Full Title: A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS 6063 in Subjects with Malignant Pleural Mesothelioma | |||||||||||||
| Medical condition: MPM is a rare but aggressive tumor of the serosal surfaces (specifically the pleura and peritoneum) that is highly invasive and progresses rapidly. The main risk factor is exposure to carcinogeni... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) SE (Prematurely Ended) NL (Completed) NO (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.